[an error occurred while processing this directive]
BBC News
watch One-Minute World News
Last Updated: Monday, 22 November, 2004, 08:40 GMT
AstraZeneca invests in UK company
The two firms are to work together on anti-inflammatory drugs
Pharmaceutical giant AstraZeneca is investing 75m ($139m) in UK firm Cambridge Antibody Technology (CAT).

The move will see the two companies work together on developing the next generation of anti-inflammatory drugs.

The announcement came as CAT, which specialises in developing drugs from anti-bodies, unveiled a drop in losses.

In the 12 months to 30 September, it made a pre-tax loss of 38m, compared to 42m for the year before. Revenues were up by 82% to 15.9m from 8.7m.

The study into anti-inflammatory drugs will initially last for five years.

Anglo-Swedish AstraZeneca is buying 10.2 million shares in CAT at 734p each, giving it an estimated 19.9% stake in CAT.

The deal is a major boost for CAT, as earlier this month it announced the failure of its biggest new drug hope.

On Monday it is also going to court with US partner Abbott over royalties to its one marketed drug.

AstraZeneca hit by drug rejection
13 Sep 04 |  Business
New drugs fuelling AstraZeneca
22 Jul 04 |  Business
AstraZeneca in $355m fraud fine
20 Jun 03 |  Business
Drug giants beat forecasts
30 Apr 03 |  Business

The BBC is not responsible for the content of external internet sites


News Front Page | Africa | Americas | Asia-Pacific | Europe | Middle East | South Asia
UK | Business | Entertainment | Science/Nature | Technology | Health
Have Your Say | In Pictures | Week at a Glance | Country Profiles | In Depth | Programmes
Americas Africa Europe Middle East South Asia Asia Pacific